US Survey Evaluated Treatment Choice in Patients With Moderate to Severe Psoriasis

According to a study published in Dermatology and Therapy, current treatment and psoriasis severity affected participants' willingness to start a new oral treatment.

Researchers aimed to systematically explore factors influencing the choice of a new once-daily oral psoriasis treatment among US adults with moderate to severe psoriasis. Conducted from December 2021 to June 2022, the study included 882 participants with a mean age of 45.7 years, of whom 67.7% were female and 74.9% were white.

Most participants (92.7%) were currently receiving treatment, with an average treatment duration of 2.9 years. About half of the participants rated their psoriasis symptoms over the past week as mild, very mild, or nonexistent, while 36.5% reported moderate symptoms, and 12.7% reported severe or very severe symptoms.

Key findings revealed that 66.5% of participants expressed a willingness to start a new oral treatment, with 65.0% believing that the new oral treatment would cause less anxiety than injections or infusions. Factors associated with the likelihood of starting the new oral treatment included current use of a tumor necrosis factor inhibitor or ustekinumab compared to apremilast, as well as the severity of psoriasis symptoms.

“Most participants indicated willingness to start a new once-daily oral treatment, viewing it as less anxiety provoking than injections/infusions,” the authors concluded.

Reference
Armstrong AW, Jayade S, Rege S, et al. Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey. Dermatol Ther (Heidelb). Published online January 22, 2024. doi:10.1007/s13555-023-01089-6